Enovis Corporation (ENOV)
| Market Cap | 1.65B -8.5% |
| Revenue (ttm) | 2.31B +3.3% |
| Net Income | -527.40M |
| EPS | -9.18 |
| Shares Out | 57.69M |
| PE Ratio | n/a |
| Forward PE | 8.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,614,483 |
| Open | 27.59 |
| Previous Close | 27.16 |
| Day's Range | 26.74 - 28.73 |
| 52-Week Range | 16.70 - 32.41 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 37.83 (+32.55%) |
| Earnings Date | Nov 5, 2026 |
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca... [Read more]
Financial Performance
In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $37.83, which is an increase of 32.55% from the latest price.
News
Enovis price target lowered to $42 from $45 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Enovis (ENOV) to $42 from $45 and keeps a Buy rating on the shares.The firm said they delivered a solid…
Enovis management to meet with BTIG
Medical Technology Analyst Zimmerman holds a Meeting with Management in New York on November 11 hosted by BTIG.
Enovis Earnings Call Transcript: Q3 2026
Q3 organic growth was 5%, with adjusted EPS up 17% YoY and improving cash generation. FY26 guidance was raised for adjusted EBITDA and EPS, while market volatility and the Middle East conflict remained headwinds.
Enovis Earnings release: Q3 2026
Enovis released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Enovis Quarterly report: Q3 2026
Enovis has published its Q3 2026 quarterly earnings report on November 5, 2026.
Enovis Slides: Q3 2026
Enovis has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Enovis reports Q3 adjusted EPS 88c, consensus 77c
Reports Q3 revenue $559M, consensus $557.15M. “Our Q3 results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and d...
Enovis raises 2026 adjusted EPS view to $3.58-$3.79 from $3.52-3.73
2026 EPS consensus $3.63. Narrows 2026 revenue view to $2.32B-$2.35B from $2.31B-$2.37B, consensus $2.34B. Revenue guidance incorporates 5% organic revenue growth, as compared to 4-6% previously. Adju...
ENOVIS Announces Third Quarter 2026 Results
Dallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial resu...
Enovis price target lowered to $34 from $52 at Needham
Needham lowered the firm’s price target on Enovis (ENOV) to $34 from $52 and keeps a Buy rating on the shares. The firm is updating its model to reflect the…
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and liv...
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Sur...
Enovis management to meet virtually with Freedom Capital
Virtual Meeting to be held on September 22 hosted by Freedom Capital.
Enovis Transcript: Wells Fargo 21st Annual Healthcare Conference
Ortho market growth remains robust, with share gains in Europe and strong U.S. performance. The eCential acquisition accelerates robotics strategy, with a U.S. knee launch in 2028 and integrated AI-powered systems. Financial targets include 50% free cash flow conversion next year and margin expansion resuming in 2028.
Enovis price target lowered to $36 from $40 at BTIG
BTIG lowered the firm’s price target on Enovis (ENOV) to $36 from $40 and keeps a Buy rating on the shares. The firm is updating its model for incremental costs…
Enovis price target lowered to $47 from $55 at Citizens
Citizens lowered the firm’s price target on Enovis (ENOV) to $47 from $55 and keeps an Outperform rating on the shares after the company announced the acquisition of eCential Robotics.
Enovis price target lowered to $36 from $40 at BTIG
BTIG lowered the firm’s price target on Enovis (ENOV) to $36 from $40 and keeps a Buy rating on the shares after the company announced a binding offer to acquire…
Enovis price target lowered to $27 from $30 at BMO Capital
BMO Capital lowered the firm’s price target on Enovis (ENOV) to $27 from $30 and keeps an Outperform rating on the shares after the company acquired eCential Robotics for EUR…
Enovis Transcript: M&A announcement
The acquisition of eCential Robotics accelerates the company’s entry into surgical robotics, focusing on knee and shoulder applications with a unified technology platform. The €155M deal, plus milestones, is expected to drive long-term growth, innovation, and margin improvement by 2029.
Enovis Slides: M&A announcement
Enovis has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Enovis Press release: M&A announcement
Enovis issued a press release on September 1, 2026, disclosing material business information to investors.
eCential Robotics Announces Binding Offer from Enovis
eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
Enovis enters binding offer to acquire eCential Robotics for EUR 155M upfront
Enovis (ENOV) announced that it has entered into a binding offer to acquire eCential Robotics. The acquisition expands the ASTRA enabling technology platform with robotic automation capabilities. Unde...
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire ...
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Farg...